2seventy bio (TSVT) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

TSVT 2seventy bio

Watchlist

2.620
-0.010-0.38%

Close Feb 25 16:00 ET

2.620
0.0000.00%

Post 16:08 ET

135.16MMarket Cap-1.43P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

2seventy Bio to Participate in the 2025 TD Cowen Healthcare Conference
BusinesswireFeb 25 07:00 ET
Novo Nordisk Eyes 2025 Regulatory Filing For Hemophilia Candidate After Encouraging Pediatric Study Data
BenzingaFeb 7 07:50 ET
Citi Maintains 2seventy Bio(TSVT.US) With Buy Rating, Cuts Target Price to $9
Moomoo NewsFeb 6 20:31 ET · Ratings
Bristol-Myers Squibb Slips as 2025 Outlook Disappoints
Seeking AlphaFeb 6 07:47 ET
2Seventy Bio Reports Preliminary Full-year U.S. Abecma Sales: Says Company Registers $242M In U.S. Abecma Sales In 2024 With Approximately $184M Of Cash And Equivalents As Of December 31
BenzingaFeb 6 07:13 ET
2seventy Bio Reports Preliminary* Full-Year U.S. Abecma Sales and Select Financial Results
BusinesswireFeb 6 07:03 ET

Comments

Jaguar8

Sep 25, 2024 06:33

NEWS

$2seventy bio (TSVT.US)$
2seventy bio Provides Update on KarMMa-9 Study and Previews Anticipated Strong Third Quarter Revenue Performance
2seventy bio and Bristol Myers Squibbhave decided to discontinue enrollment in the Phase 3 KarMMa-9 studyevaluating Abecma in newly diagnosed multiple myeloma patients. This decision is expected to result in over $80 million in cost savings for 2seventy bio and accelerate their path to breakeven in 2025.
The company reports positive momentum for Abecma, wi...

Stock_Drift

Sep 25, 2024 05:08

$2seventy bio (TSVT.US)$

Trytosaveabit

Apr 25, 2024 06:11

$2seventy bio (TSVT.US)$ 2Seventy Bio Inc: Abecma (Idecabtagene Vicleucel, or Ide-Cel) Generated Approximately $52 Mln in U.S. Revenue During Q1 of 2024

Meltyy

Apr 9, 2024 10:48

FDA PDUFA Update…

🗓️ Last week’s PDUFAs:
$Supernus Pharmaceuticals (SUPN.US)$ : CRL 4/8/24 🙁
⇒ SPN-830
⇒ OFF episodes in PD
⇒ NDA
⇒ PDUFA: 4/5/24
$Legend Biotech (LEGN.US)$ & $Johnson & Johnson (JNJ.US)$ : Approved 🎉
⇒ CARVYKTI (cilta-cel)
⇒ Multiple myeloma
⇒ sBLA
⇒ PDUFA: 4/5/24
$AstraZeneca (AZN.US)$ : Approved 🎉
⇒ Enhertu
⇒ HER2+ solid tumors
⇒ sBLA
⇒ PDUFA: Q2 2024
$2seventy bio (TSVT.US)$ & $Bristol-Myers Squibb (BMY.US)$ : Approved 🎉
⇒ Abecma
⇒ Multiple myeloma
⇒ sBLA
⇒ Delayed PDUFA
$Vanda Pharmaceuticals (VNDA.US)$...